POET Technologies: A Photonics Pioneer's Credibility Battle Overshadows a $50 Million Order

POET Technologies faces a 70% stock decline from May highs, weighed down by a shareholder class action, a cancelled Marvell order, and legal uncertainty, despite securing $830M in financing and advancing production plans.

The story of POET Technologies in 2026 has become a study in contrasts. On one hand, the company has secured roughly $830 million in equity financing over the past twelve months, landed a $50 million initial order from Lumilens with the potential to grow to $500 million, and is pushing toward a production capacity of one million optical engine units per month by the end of 2027. On the other hand, its stock has shed roughly 70 percent from the May high of €18.84, and a shareholder class action — combined with the fallout from a cancelled customer relationship — has left investors questioning whether execution can outpace legal and reputational headwinds.

The shares attempted a modest bounce on Wednesday, rising 1.35 percent to €6.01, before sliding again in subsequent sessions to €5.57, a decline of 6.07 percent on the day. Over the trailing 30 trading days, the cumulative loss stands at 38.18 percent. The 14-day relative strength index has dropped to 34, brushing the edge of oversold territory, but no sustained recovery has materialized.

The Legal Overhang That Won't Fade

At the heart of the selling pressure is a class action lawsuit that accuses POET of misrepresenting its tax status as a Passive Foreign Investment Company. Several law firms have alleged that U.S. shareholders were not adequately warned about adverse tax treatment during the 2026 class period. The deadline for lead plaintiff applications passed on June 29, 2026, but the legal uncertainty continues to weigh on sentiment.

More damaging still was a separate incident involving a senior manager who allegedly breached a confidentiality agreement during a public interview. The consequence was swift and severe: Marvell Technology's Celestial AI unit cancelled all outstanding orders with POET. That single event triggered an intraday collapse of 45 to 47 percent earlier this year, a move that short sellers exploited aggressively. The combination of credibility concerns, complex tax litigation, and high customer concentration has created a toxic mix for the stock.

Production Plans Remain on Track

Despite the market's skepticism, management has not wavered from its operational roadmap. The production ramp of integrated optical engines is scheduled for the second half of 2026, supported by roughly $50 million in capital expenditures. Those funds are earmarked for expanding assembly and test capacity within POET's Malaysian manufacturing network, including approximately 20,000 square feet of additional floor space.

The current production focus is on 800G and 1.6T optical modules built on the company's proprietary Optical Interposer platform. A next-generation effort is also underway: a partnership with Quantum Computing Inc., announced in November 2025, aims to develop 3.2 Tbps optical modules combining high-performance modulators at 400G per channel with POET's platform. Completion is targeted for the second half of 2026 as well.

By the end of 2027, POET intends to scale monthly production capacity to one million units — more than ten times the current level. The company has also disclosed more than ten active customer relationships that it believes could generate annual revenue exceeding $100 million. The Lumilens order for EOI-based engines, valued at $50 million initially, is the most concrete evidence of commercial traction to date.

A Stock Caught Between Promise and Proof

The market capitalization has shrunk to roughly €417.5 million, a fraction of the valuation at the May peak. The stock trades well below its 200-day moving average of €6.84 and remains 68.10 percent off the May high of €18.84, though it still holds above the November trough of €3.40.

The RSI reading of 36.8 on one session and 34 on another suggests the stock is approaching levels that have historically attracted value-oriented buyers. But technical indicators alone are unlikely to reverse the trend. The broader sell-off in AI hardware names has compounded POET's woes, and the legal overhang provides a persistent drag that sentiment-driven rallies cannot easily overcome.

For the stock to stage a meaningful recovery, the company will need to deliver verifiable revenue from its production ramp and resolve — or at least diminish — the legal distractions. The second half of 2026 represents a critical proving ground. If POET's Malaysian partners can deliver volume shipments and the Lumilens relationship expands as projected, the narrative could shift from one of crisis management to execution credibility. Until then, the stock remains a high-volatility battleground where the gap between a well-funded vision and market reality has rarely been wider.